Cargando…

Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis

Intravascular hemolysis of any cause can induce acute kidney injury (AKI). Hemolysis-derived product heme activates the innate immune complement system and contributes to renal damage. Therefore, we explored the role of the master complement regulator Factor H (FH) in the kidney's resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Merle, Nicolas S., Leon, Juliette, Poillerat, Victoria, Grunenwald, Anne, Boudhabhay, Idris, Knockaert, Samantha, Robe-Rybkine, Tania, Torset, Carine, Pickering, Matthew C., Chauvet, Sophie, Fremeaux-Bacchi, Veronique, Roumenina, Lubka T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426730/
https://www.ncbi.nlm.nih.gov/pubmed/32849636
http://dx.doi.org/10.3389/fimmu.2020.01772
Descripción
Sumario:Intravascular hemolysis of any cause can induce acute kidney injury (AKI). Hemolysis-derived product heme activates the innate immune complement system and contributes to renal damage. Therefore, we explored the role of the master complement regulator Factor H (FH) in the kidney's resistance to hemolysis-mediated AKI. Acute systemic hemolysis was induced in mice lacking liver expression of FH (hepatoFH(−/−), ~20% residual FH) and in WT controls, by phenylhydrazine injection. The impaired complement regulation in hepatoFH(−/−) mice resulted in a delayed but aggravated phenotype of hemolysis-related kidney injuries. Plasma urea as well as markers for tubular (NGAL, Kim-1) and vascular aggression peaked at day 1 in WT mice and normalized at day 2, while they increased more in hepatoFH(−/−) compared to the WT and still persisted at day 4. These were accompanied by exacerbated tubular dilatation and the appearance of tubular casts in the kidneys of hemolytic hepatoFH(−/−) mice. Complement activation in hemolytic mice occurred in the circulation and C3b/iC3b was deposited in glomeruli in both strains. Both genotypes presented with positive staining of FH in the glomeruli, but hepatoFH(−/−) mice had reduced staining in the tubular compartment. Despite the clear phenotype of tubular injury, no complement activation was detected in the tubulointerstitium of the phenylhydrazin-injected mice irrespective of the genotype. Nevertheless, phenylhydrazin triggered overexpression of C5aR1 in tubules, predominantly in hepatoFH(−/−) mice. Moreover, C5b-9 was deposited only in the glomeruli of the hemolytic hepatoFH(−/−) mice. Therefore, we hypothesize that C5a, generated in the glomeruli, could be filtered into the tubulointerstitium to activate C5aR1 expressed by tubular cells injured by hemolysis-derived products and will aggravate the tissue injury. Plasma-derived FH is critical for the tubular protection, since pre-treatment of the hemolytic hepatoFH(−/−) mice with purified FH attenuated the tubular injury. Worsening of acute tubular necrosis in the hepatoFH(−/−) mice was trigger-dependent, as it was also observed in LPS-induced septic AKI model but not in chemotherapy-induced AKI upon cisplatin injection. In conclusion, plasma FH plays a key role in protecting the kidneys, especially the tubules, against hemolysis-mediated injury. Thus, FH-based molecules might be explored as promising therapeutic agents in a context of AKI.